Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK)
The present study, which was designed as a prospective, double-masked, randomized, controlled, single-site study, was conducted to compare the effects of 3 approved ophthalmic nonsteroidal anti-inflammatory drugs-nepafenac ophthalmic suspension 0.1% (Nevanac; Alcon Laboratories, Inc., Fort Worth, Te...
Gespeichert in:
| Veröffentlicht in: | Advances in therapy 2007-11, Vol.24 (6), p.1278-1285 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1285 |
|---|---|
| container_issue | 6 |
| container_start_page | 1278 |
| container_title | Advances in therapy |
| container_volume | 24 |
| creator | Durrie, Daniel S Kennard, Marla G Boghossian, Allen J |
| description | The present study, which was designed as a prospective, double-masked, randomized, controlled, single-site study, was conducted to compare the effects of 3 approved ophthalmic nonsteroidal anti-inflammatory drugs-nepafenac ophthalmic suspension 0.1% (Nevanac; Alcon Laboratories, Inc., Fort Worth, Tex), ketorolac tromethamine ophthalmic solution 0.4% (Acular LS; Allergan, Irvine, Calif), and bromfenac 0.09% (Xibromtrade mark; ISTA Pharmaceuticals, Irvine, Calif)-on corneal reepithelialization and postoperative pain control in patients undergoing photorefractive keratectomy. In addition to nonsteroidal anti-inflammatory drugs, each patient received an antibiotic-moxifloxacin hydrochloride ophthalmic solution 0.5% (nepafenac group) or gatifloxacin ophthalmic solution 0.3% (ketorolac and bromfenac groups). All treatments were administered 3 times daily beginning 1 d preoperatively and continuing for 1 wk postoperatively; prednisolone acetate 1.0% was administered concurrently 4 times daily. Bandage contact lenses were replaced at each postoperative visit for corneal staining and epithelial defect grading. Self-evaluation of pain relief was recorded on postoperative days 1 and 3 with the use of a visual analog scale. A total of 29 patients (58 eyes) were enrolled and underwent bilateral custom photorefractive keratectomy. Mean time to reepithelialization was 5.50+/-1.59 d for the nepafenac 0.1% group, 5.62+/-1.23 d for the ketorolac 0.4% group, and 7.25+/-2.53 d for the bromfenac 0.09% group. A significant difference was detected between nepafenac 0.1% and bromfenac 0.09% and between ketorolac 0.4% and bromfenac 0.09% (P |
| doi_str_mv | 10.1007/BF02877774 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69085385</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69085385</sourcerecordid><originalsourceid>FETCH-LOGICAL-c285t-ff32ad1157026ba2a13248440af2ebe6fc0abc4ca19291ffb13ddcdb4afa56083</originalsourceid><addsrcrecordid>eNpFkMtKBDEQRYMoOo5u_ADJSlRoTdKvzFIHXzigiIK7pjoPO9qdtElGmF_wq404YLghUHXqprgIHVByRgmpzy-vCeN1OsUGmlBelVm6bBNNSF3QjOX8dQfthvBOCCN1ybfRDuU0EZRM0PeV1krEgJ3G1tkQlXdGQo_d2MUO-sEILL0bE2CxGk3sVG9Su1PQG_uGwUo8grE4aYRolE1eSyuVf3O__db0kDzTxNi56LzSHkQ0Xwp_pGpMX7thhY8fn-5P9tCWhj6o_fU7RS_XV8_z22zxcHM3v1hkgvEyZlrnDCSlZU1Y1QIDmrOCFwUBzVSrKi0ItKIQQGdsRrVuaS6lkG0BGsqK8HyKjv58R-8-lyrEZjBBqL4Hq9wyNNWM8DJPmqLTP1B4F0JavRm9GcCvGkqa3-Sb_-QTfLh2XbaDkv_oOur8B9SJgbk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69085385</pqid></control><display><type>article</type><title>Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK)</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Durrie, Daniel S ; Kennard, Marla G ; Boghossian, Allen J</creator><creatorcontrib>Durrie, Daniel S ; Kennard, Marla G ; Boghossian, Allen J</creatorcontrib><description>The present study, which was designed as a prospective, double-masked, randomized, controlled, single-site study, was conducted to compare the effects of 3 approved ophthalmic nonsteroidal anti-inflammatory drugs-nepafenac ophthalmic suspension 0.1% (Nevanac; Alcon Laboratories, Inc., Fort Worth, Tex), ketorolac tromethamine ophthalmic solution 0.4% (Acular LS; Allergan, Irvine, Calif), and bromfenac 0.09% (Xibromtrade mark; ISTA Pharmaceuticals, Irvine, Calif)-on corneal reepithelialization and postoperative pain control in patients undergoing photorefractive keratectomy. In addition to nonsteroidal anti-inflammatory drugs, each patient received an antibiotic-moxifloxacin hydrochloride ophthalmic solution 0.5% (nepafenac group) or gatifloxacin ophthalmic solution 0.3% (ketorolac and bromfenac groups). All treatments were administered 3 times daily beginning 1 d preoperatively and continuing for 1 wk postoperatively; prednisolone acetate 1.0% was administered concurrently 4 times daily. Bandage contact lenses were replaced at each postoperative visit for corneal staining and epithelial defect grading. Self-evaluation of pain relief was recorded on postoperative days 1 and 3 with the use of a visual analog scale. A total of 29 patients (58 eyes) were enrolled and underwent bilateral custom photorefractive keratectomy. Mean time to reepithelialization was 5.50+/-1.59 d for the nepafenac 0.1% group, 5.62+/-1.23 d for the ketorolac 0.4% group, and 7.25+/-2.53 d for the bromfenac 0.09% group. A significant difference was detected between nepafenac 0.1% and bromfenac 0.09% and between ketorolac 0.4% and bromfenac 0.09% (P<.05). Significant reductions in pain scores were observed with nepafenac 0.1% on day 1 (-1.13) and day 3 (-1.32), ketorolac 0.4% on day 3 (-0.88), and bromfenac 0.09% on day 3 (-0.83). No adverse events were reported. Eyes treated with nepafenac 0.1% or ketorolac 0.4% achieved complete reepithelialization significantly faster than those treated with bromfenac 0.09%. Daily contact lens removal and application of fluorescein may have delayed reepithelialization in the overall population; however, the effect would have been the same in all 3 groups. Pain relief with nepafenac 0.1% was achieved sooner than with ketorolac 0.4% or bromfenac 0.09%.</description><identifier>ISSN: 0741-238X</identifier><identifier>EISSN: 1865-8652</identifier><identifier>DOI: 10.1007/BF02877774</identifier><identifier>PMID: 18165210</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Aged ; Anti-Bacterial Agents - therapeutic use ; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Benzeneacetamides - therapeutic use ; Benzophenones - therapeutic use ; Bromobenzenes - therapeutic use ; Double-Blind Method ; Drug Therapy, Combination ; Epithelium, Corneal - drug effects ; Epithelium, Corneal - physiopathology ; Female ; Health technology assessment ; Humans ; Ketorolac Tromethamine - therapeutic use ; Lasers, Excimer ; Male ; Middle Aged ; Ophthalmic Solutions ; Pain, Postoperative - drug therapy ; Phenylacetates - therapeutic use ; Photorefractive Keratectomy ; Prednisolone - analogs & derivatives ; Prednisolone - therapeutic use ; Prospective Studies ; Wound Healing</subject><ispartof>Advances in therapy, 2007-11, Vol.24 (6), p.1278-1285</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c285t-ff32ad1157026ba2a13248440af2ebe6fc0abc4ca19291ffb13ddcdb4afa56083</citedby><cites>FETCH-LOGICAL-c285t-ff32ad1157026ba2a13248440af2ebe6fc0abc4ca19291ffb13ddcdb4afa56083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18165210$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Durrie, Daniel S</creatorcontrib><creatorcontrib>Kennard, Marla G</creatorcontrib><creatorcontrib>Boghossian, Allen J</creatorcontrib><title>Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK)</title><title>Advances in therapy</title><addtitle>Adv Ther</addtitle><description>The present study, which was designed as a prospective, double-masked, randomized, controlled, single-site study, was conducted to compare the effects of 3 approved ophthalmic nonsteroidal anti-inflammatory drugs-nepafenac ophthalmic suspension 0.1% (Nevanac; Alcon Laboratories, Inc., Fort Worth, Tex), ketorolac tromethamine ophthalmic solution 0.4% (Acular LS; Allergan, Irvine, Calif), and bromfenac 0.09% (Xibromtrade mark; ISTA Pharmaceuticals, Irvine, Calif)-on corneal reepithelialization and postoperative pain control in patients undergoing photorefractive keratectomy. In addition to nonsteroidal anti-inflammatory drugs, each patient received an antibiotic-moxifloxacin hydrochloride ophthalmic solution 0.5% (nepafenac group) or gatifloxacin ophthalmic solution 0.3% (ketorolac and bromfenac groups). All treatments were administered 3 times daily beginning 1 d preoperatively and continuing for 1 wk postoperatively; prednisolone acetate 1.0% was administered concurrently 4 times daily. Bandage contact lenses were replaced at each postoperative visit for corneal staining and epithelial defect grading. Self-evaluation of pain relief was recorded on postoperative days 1 and 3 with the use of a visual analog scale. A total of 29 patients (58 eyes) were enrolled and underwent bilateral custom photorefractive keratectomy. Mean time to reepithelialization was 5.50+/-1.59 d for the nepafenac 0.1% group, 5.62+/-1.23 d for the ketorolac 0.4% group, and 7.25+/-2.53 d for the bromfenac 0.09% group. A significant difference was detected between nepafenac 0.1% and bromfenac 0.09% and between ketorolac 0.4% and bromfenac 0.09% (P<.05). Significant reductions in pain scores were observed with nepafenac 0.1% on day 1 (-1.13) and day 3 (-1.32), ketorolac 0.4% on day 3 (-0.88), and bromfenac 0.09% on day 3 (-0.83). No adverse events were reported. Eyes treated with nepafenac 0.1% or ketorolac 0.4% achieved complete reepithelialization significantly faster than those treated with bromfenac 0.09%. Daily contact lens removal and application of fluorescein may have delayed reepithelialization in the overall population; however, the effect would have been the same in all 3 groups. Pain relief with nepafenac 0.1% was achieved sooner than with ketorolac 0.4% or bromfenac 0.09%.</description><subject>Adult</subject><subject>Aged</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Benzeneacetamides - therapeutic use</subject><subject>Benzophenones - therapeutic use</subject><subject>Bromobenzenes - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Epithelium, Corneal - drug effects</subject><subject>Epithelium, Corneal - physiopathology</subject><subject>Female</subject><subject>Health technology assessment</subject><subject>Humans</subject><subject>Ketorolac Tromethamine - therapeutic use</subject><subject>Lasers, Excimer</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Ophthalmic Solutions</subject><subject>Pain, Postoperative - drug therapy</subject><subject>Phenylacetates - therapeutic use</subject><subject>Photorefractive Keratectomy</subject><subject>Prednisolone - analogs & derivatives</subject><subject>Prednisolone - therapeutic use</subject><subject>Prospective Studies</subject><subject>Wound Healing</subject><issn>0741-238X</issn><issn>1865-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMtKBDEQRYMoOo5u_ADJSlRoTdKvzFIHXzigiIK7pjoPO9qdtElGmF_wq404YLghUHXqprgIHVByRgmpzy-vCeN1OsUGmlBelVm6bBNNSF3QjOX8dQfthvBOCCN1ybfRDuU0EZRM0PeV1krEgJ3G1tkQlXdGQo_d2MUO-sEILL0bE2CxGk3sVG9Su1PQG_uGwUo8grE4aYRolE1eSyuVf3O__db0kDzTxNi56LzSHkQ0Xwp_pGpMX7thhY8fn-5P9tCWhj6o_fU7RS_XV8_z22zxcHM3v1hkgvEyZlrnDCSlZU1Y1QIDmrOCFwUBzVSrKi0ItKIQQGdsRrVuaS6lkG0BGsqK8HyKjv58R-8-lyrEZjBBqL4Hq9wyNNWM8DJPmqLTP1B4F0JavRm9GcCvGkqa3-Sb_-QTfLh2XbaDkv_oOur8B9SJgbk</recordid><startdate>200711</startdate><enddate>200711</enddate><creator>Durrie, Daniel S</creator><creator>Kennard, Marla G</creator><creator>Boghossian, Allen J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200711</creationdate><title>Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK)</title><author>Durrie, Daniel S ; Kennard, Marla G ; Boghossian, Allen J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c285t-ff32ad1157026ba2a13248440af2ebe6fc0abc4ca19291ffb13ddcdb4afa56083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Benzeneacetamides - therapeutic use</topic><topic>Benzophenones - therapeutic use</topic><topic>Bromobenzenes - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Epithelium, Corneal - drug effects</topic><topic>Epithelium, Corneal - physiopathology</topic><topic>Female</topic><topic>Health technology assessment</topic><topic>Humans</topic><topic>Ketorolac Tromethamine - therapeutic use</topic><topic>Lasers, Excimer</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Ophthalmic Solutions</topic><topic>Pain, Postoperative - drug therapy</topic><topic>Phenylacetates - therapeutic use</topic><topic>Photorefractive Keratectomy</topic><topic>Prednisolone - analogs & derivatives</topic><topic>Prednisolone - therapeutic use</topic><topic>Prospective Studies</topic><topic>Wound Healing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Durrie, Daniel S</creatorcontrib><creatorcontrib>Kennard, Marla G</creatorcontrib><creatorcontrib>Boghossian, Allen J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Advances in therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Durrie, Daniel S</au><au>Kennard, Marla G</au><au>Boghossian, Allen J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK)</atitle><jtitle>Advances in therapy</jtitle><addtitle>Adv Ther</addtitle><date>2007-11</date><risdate>2007</risdate><volume>24</volume><issue>6</issue><spage>1278</spage><epage>1285</epage><pages>1278-1285</pages><issn>0741-238X</issn><eissn>1865-8652</eissn><abstract>The present study, which was designed as a prospective, double-masked, randomized, controlled, single-site study, was conducted to compare the effects of 3 approved ophthalmic nonsteroidal anti-inflammatory drugs-nepafenac ophthalmic suspension 0.1% (Nevanac; Alcon Laboratories, Inc., Fort Worth, Tex), ketorolac tromethamine ophthalmic solution 0.4% (Acular LS; Allergan, Irvine, Calif), and bromfenac 0.09% (Xibromtrade mark; ISTA Pharmaceuticals, Irvine, Calif)-on corneal reepithelialization and postoperative pain control in patients undergoing photorefractive keratectomy. In addition to nonsteroidal anti-inflammatory drugs, each patient received an antibiotic-moxifloxacin hydrochloride ophthalmic solution 0.5% (nepafenac group) or gatifloxacin ophthalmic solution 0.3% (ketorolac and bromfenac groups). All treatments were administered 3 times daily beginning 1 d preoperatively and continuing for 1 wk postoperatively; prednisolone acetate 1.0% was administered concurrently 4 times daily. Bandage contact lenses were replaced at each postoperative visit for corneal staining and epithelial defect grading. Self-evaluation of pain relief was recorded on postoperative days 1 and 3 with the use of a visual analog scale. A total of 29 patients (58 eyes) were enrolled and underwent bilateral custom photorefractive keratectomy. Mean time to reepithelialization was 5.50+/-1.59 d for the nepafenac 0.1% group, 5.62+/-1.23 d for the ketorolac 0.4% group, and 7.25+/-2.53 d for the bromfenac 0.09% group. A significant difference was detected between nepafenac 0.1% and bromfenac 0.09% and between ketorolac 0.4% and bromfenac 0.09% (P<.05). Significant reductions in pain scores were observed with nepafenac 0.1% on day 1 (-1.13) and day 3 (-1.32), ketorolac 0.4% on day 3 (-0.88), and bromfenac 0.09% on day 3 (-0.83). No adverse events were reported. Eyes treated with nepafenac 0.1% or ketorolac 0.4% achieved complete reepithelialization significantly faster than those treated with bromfenac 0.09%. Daily contact lens removal and application of fluorescein may have delayed reepithelialization in the overall population; however, the effect would have been the same in all 3 groups. Pain relief with nepafenac 0.1% was achieved sooner than with ketorolac 0.4% or bromfenac 0.09%.</abstract><cop>United States</cop><pmid>18165210</pmid><doi>10.1007/BF02877774</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0741-238X |
| ispartof | Advances in therapy, 2007-11, Vol.24 (6), p.1278-1285 |
| issn | 0741-238X 1865-8652 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69085385 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adult Aged Anti-Bacterial Agents - therapeutic use Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Benzeneacetamides - therapeutic use Benzophenones - therapeutic use Bromobenzenes - therapeutic use Double-Blind Method Drug Therapy, Combination Epithelium, Corneal - drug effects Epithelium, Corneal - physiopathology Female Health technology assessment Humans Ketorolac Tromethamine - therapeutic use Lasers, Excimer Male Middle Aged Ophthalmic Solutions Pain, Postoperative - drug therapy Phenylacetates - therapeutic use Photorefractive Keratectomy Prednisolone - analogs & derivatives Prednisolone - therapeutic use Prospective Studies Wound Healing |
| title | Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T02%3A57%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20nonsteroidal%20ophthalmic%20drops%20on%20epithelial%20healing%20and%20pain%20in%20patients%20undergoing%20bilateral%20photorefractive%20keratectomy%20(PRK)&rft.jtitle=Advances%20in%20therapy&rft.au=Durrie,%20Daniel%20S&rft.date=2007-11&rft.volume=24&rft.issue=6&rft.spage=1278&rft.epage=1285&rft.pages=1278-1285&rft.issn=0741-238X&rft.eissn=1865-8652&rft_id=info:doi/10.1007/BF02877774&rft_dat=%3Cproquest_cross%3E69085385%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69085385&rft_id=info:pmid/18165210&rfr_iscdi=true |